Bi- & Multispecific Molecular Design with Improved Therapeutic Windows through Rational Target Pairing

• Highlighting differentiated target identification for first-in-class multispecific drugs
• Benchmarking to known approved TCE drugs
• Leveraging dual targeting to expand therapeutic window and patient prevalence

Speakers:

Christian Rohlff

Chief Executive Officer

Oxford BioTherapeutics Ltd